First cannabis-derived drug authorised for France

January 9, 2014

France has for the first time approved prescription use of a drug derived from cannabis—a mouth spray used to treat multiple sclerosis (MS) symptoms, the government said Thursday.

The medicine, called Sativex, is already authorised in several European neighbours, but had remained off-limits in France due to a ban on any products derived from the marijuana plant.

The health ministry published a policy change last June, opening the door for medical use of the drug's active ingredients.

The first market authorisation was given on Wednesday by the National Agency for Drug Safety (ANSM), the ministry said.

Sativex, produced by the British firm GW Pharmaceuticals, has been approved for use in alleviating muscle stiffness and spasms from MS.

"The market authorisation is an interim step" before the drug becomes available from pharmacies, but on prescription only, said a ministry statement.

The spray's main active ingredients are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).

ANSM official Nathalie Richard said Sativex was not recommended for breastfeeding or pregnant women or people with a history of psychosis.

Medical cannabis use is already a reality in countries like the Netherlands, Spain, Italy, Germany and Britain, Canada, Australia and some American states.

In Canada, Sativex is also used to alleviate pain associated with cancer.

New York Governor Andrew Cuomo announced Wednesday he will authorise medical marijuana use, making his the 21st US state to do so.

Explore further: Czechs award first licence to import medical marijuana

Related Stories

Czechs award first licence to import medical marijuana

November 19, 2013
The Czech health ministry said Tuesday it had awarded its first licence to import marijuana, months after the European Union member legalised the drug for medical purposes.

Pot-based prescription drug looks for FDA OK

January 23, 2012
A quarter-century after the U.S. Food and Drug Administration approved the first prescription drugs based on the main psychoactive ingredient in marijuana, additional medicines derived from or inspired by the cannabis plant ...

No strong evidence to back use of cannabis extract in multiple sclerosis

December 12, 2012
There is no strong evidence to back the use of cannabis extract in the treatment of Multiple Sclerosis (MS), concludes a review of the available evidence on the first licensed preparation, published in the December issue ...

Washington state approves rules for pot industry

October 16, 2013
Washington became the second U.S. state to adopt rules for the recreational sale of marijuana Wednesday, setting what advocates hope will become a template for the drug's legalization around the world.

Czechs in quandary over legal medical marijuana

November 15, 2013
(AP)—Just three years ago, the only thing that Zdenek Majzlik knew about cannabis was that it's good stuff for making rope. Today, the 67-year-old retired nuclear power plant employee is an experienced grower who cultivates ...

Uruguay marijuana draws pharmaceuticals' interest: report

January 6, 2014
Foreign pharmaceutical companies have expressed interest in buying marijuana for medical uses from Uruguay, which last month became the world's first country to legalize the cultivation and sale of the drug, local media reported ...

Recommended for you

Mind-body therapies immediately reduce unmanageable pain in hospital patients

July 25, 2017
Mindfulness training and hypnotic suggestion significantly reduced acute pain experienced by hospital patients, according to a new study published in the Journal of General Internal Medicine.

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.